natgillin/translations-raw huggingface dataset:
Dapagliflozin as an add-on to metformin alone or metformin plus sitagliptin, sulphonylurea or insulin (with or without additional oral glucose-lowering medicinal products, including metformin) resulted in statistically significant body weight reduction up to 24 weeks (p < 0.0001, Tables 3, 4 and 5).
Dapagliflozin kot dodatek metforminu samemu ali metforminu v kombinaciji s sitagliptinom, sulfonilsečnino ali insulinom (z dodatnimi peroralnimi zdravili za znižanje glukoze (vključno z metforminom) ali brez njih) je do 24. tedna statistično značilno znižal telesno maso (p < 0,0001, preglednice 3, 4 in 5).
Dapagliflozin as an add-on with either metformin alone, metformin in combination with sitagliptin, sulphonylurea, or insulin (with or without additional oral glucose-lowering medicinal products, including metformin) resulted in statistically significant mean reductions in HbA1c at 24 weeks compared with subjects receiving placebo (p < 0.0001; Tables 3, 4 and 5).
Dapagliflozin kot dodatek bodisi metforminu samemu, metforminu v kombinaciji s sitagliptinom, sulfonilsečnino ali insulinom (z dodatnimi peroralnimi antidiabetiki (vključno z metforminom) ali brez njih) je po 24 tednih statistično značilno znižal HbA1c v primerjavi s prejemniki placeba (p < 0.0001, preglednice 3, 4 in 5).
Dapagliflozin exposure increased proportional to the increment in dapagliflozin dose over the range of
Izpostavljenost dapagliflozinu se je v razponu odmerkov od 0,1 do 500 mg povečevala sorazmerno povečanju odmerka.
Dapagliflozin exposure increased proportional to the increment in dapagliflozin dose over the range of
Izpostavljenost dapagliflozinu se je v razponu odmerkov od 0,1 do 500 mg povečevala sorazmerno s povečevanjem odmerka.
Dapagliflozin has been authorised in the European Union (EU) as Forxiga since 2012; metformin works mainly by inhibiting glucose production and reducing its absorption in the gut.
Dapagliflozin je v Evropski uniji odobren od leta 2012 kot zdravilo Forxiga; metformin deluje predvsem tako, da zavira tvorbo glukoze in zmanjšuje njeno absorpcijo v črevesju.
Dapagliflozin has been authorised in the European Union (EU) as Forxiga since 2012; saxagliptin, is a dipeptidyl-peptidase-4 (DPP-4) inhibitor.
Dapagliflozin je v Evropski uniji (EU) odobren od leta 2012 kot zdravilo Forxiga; saksagliptin je zaviralec dipeptidil-peptidaze-4 (DPP-4).
Dapagliflozin has not been studied in combination with glucagon-like peptide 1 (GLP-1) analogues.
Dapagliflozin ni bil raziskan v kombinaciji z analogi glukagonu podobnega peptida 1 (GLP-1 – glucagon-like peptide 1).
Dapagliflozin has not been studied in combination with glucagon-like peptide 1 (GLP-1) analogues.
Dapagliflozin ni raziskan v kombinaciji z analogi glukagonu podobnega peptida 1 (GLP-1).
Dapagliflozin is a highly potent (Ki: 0.55 nM), selective and reversible inhibitor of sodium-glucose co-transporter 2 (SGLT2).
Dapagliflozin je zelo močan (Ki: 0,55 nM), selektivni in reverzibilni zaviralec natrij-glukoznega koprenašalca 2 (SGLT2 – sodium glucose co-transporter 2).
Dapagliflozin Pharmacodynamic interactions Diuretics
Dapagliflozin Farmakodinamično medsebojno delovanje Diuretiki
dapagliflozin works by blocking a protein in the kidneys called sodium-glucose co-transporter 2 (SGLT2).
dapagliflozin zavira beljakovino v ledvicah, imenovano natrij-glukozni soprenašalec 2 (SGLT2).
dapagliflozin works by blocking a protein in the kidneys called sodium-glucose co-transporter 2 (SGLT2).
dapagliflozin zavira beljakovino v ledvicah, imenovano natrijev-glukozni koprenašalec 2 (SGLT2 – sodium glucose co-transporter 2).
Dapagliflozin: Dapagliflozin is extensively metabolised, primarily to yield dapagliflozin 3-O-glucuronide, which is an inactive metabolite.
Dapagliflozin: Dapagliflozin se obsežno presnovi, predvsem z nastankom dapagliflozin-3-O- glukuronida, ki je neaktiven presnovek.
Dapagliflozin: In in vitro studies, dapagliflozin neither inhibited cytochrome P450 (CYP) 1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4, nor induced CYP1A2,
Dapagliflozin: V študijah in vitro dapagliflozin ni ne zavrl citokroma P450 (CYP) 1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4, ne induciral CYP1A2, CYP2B6 ali
Dapagliflozin’s glucuretic effect is observed after the first dose, is continuous over the 24-hour dosing interval, and is sustained for the duration of treatment.
Glukuretični učinek dapagliflozina je opazen po prvem odmerku, je stalen v 24-urnem intervalu odmerjanja in se med obdobjem zdravljenja ohrani.
dapsone, to prevent pneumonia and treat skin infections
dapson za preprečevanje pljučnice in zdravljenje okužb kože,
dapsone, to prevent pneumonia and treat skin infections
dapson, za preprečevanje pljučnice in zdravljenje okužb kože;
Daptomycin exhibits rapid, concentration dependent bactericidal activity against Gram positive organisms in vitro and in in vivo animal models.
Daptomicin ima hiter, od koncentracije odvisen baktericiden učinek proti po Gramu pozitivnim organizmom na živalskih modelih in vitro in in vivo.
Daptomycin is a cyclic lipopeptide natural product that is active against Gram positive bacteria only.
Daptomicin je ciklični lipopeptid naravnega izvora, ki deluje samo proti po Gramu pozitivnim bakterijam.
Daptomycin is active against Gram positive bacteria only (see section 5.1).
Daptomicin deluje samo proti po Gramu pozitivnim bakterijam (glejte poglavje 5.1).
Daptomycin is eliminated primarily by the kidney.
Daptomicin se izloča primarno preko ledvic.
Daptomycin is primarily cleared by renal filtration and so plasma levels may be increased during co- administration with medicinal products that reduce renal filtration (e.g.
Daptomicin se primarno izloča z ledvično filtracijo, tako da se lahko pri sočasni uporabi zdravil, ki zavirajo ledvično filtracijo (npr.
Daptomycin may be administered intravenously as an infusion over 30 or 60 minutes or as an injection over 2 minutes (see sections 4.2 and 5.2).
Daptomicin je mogoče aplicirati intravensko v obliki infuzije, ki traja 30 ali 60 minut, ali v obliki injekcije, ki traja 2 minuti (glejte poglavji 4.2 in 5.2).
Daptomycin may be administered intravenously as an infusion over 30 or 60 minutes or as an injection over 2 minutes.
Daptomicin je mogoče aplicirati intravensko v obliki infuzije, ki traja 30 ali 60 minut, ali v obliki injekcije, ki traja 2 minuti.
Daptomycin pharmacokinetics are generally linear and time-independent at doses of 4 to 12 mg/kg administered as a single daily dose by 30-minute intravenous infusion for up to 14 days in healthy volunteers.
Farmakokinetika daptomicina je pri odmerkih od 4 do 12 mg/kg, danih zdravim prostovoljcem v enkratnem dnevnem odmerku s 30-minutno intravensko infuzijo do 14 dni, običajno linearna in neodvisna od časa.
Daptomycin undergoes little to no Cytochrome P450 (CYP450)-mediated metabolism.
Daptomicin je metabolizmu, ki je odvisen od citokroma P450 (CYP 450), če sploh, le malo podvržen.
Daratumumab bound to Red Blood Cells (RBCs) may mask the detection of antibodies to minor antigens in the patient’s serum;
Na eritrocite vezani daratumumab lahko moti določanje protiteles proti manjšim antigenom v bolnikovem serumu.
Daratumumab has not been studied in patients with moderate to severe hepatic impairment (TB > 1.5 x ULN and any AST), therefore no dose recommendations can be made in these patient populations (see section 5.2).
Uporabe daratumumaba niso proučevali pri bolnikih z zmerno do hudo okvaro jeter (s koncentracijo celotnega bilirubina nad 1,5-kratnikom ZMN pri kakršnikoli koncentraciji AST), zato za to skupino bolnikov ni mogoče dati priporočil za odmerjanje (glejte poglavje 5.2).
Daratumumab may be detected on serum protein electrophoresis (SPE) and immunofixation (IFE) assays used for monitoring disease monoclonal immunoglobulins (M protein).
Daratumumab lahko zaznamo z elektroforezo serumskih proteinov in imunofiksacijo, ki se uporabljata za spremljanje monoklonskega imunoglobulina diseminiranega plazmocitoma (M-protein).
Daratumumab-mediated positive indirect Coombs test may persist for up to 6 months after the last daratumumab infusion.
Rezultati indirektnega Coombsovega testa so lahko pozitivni zaradi daratumumaba še do 6 mesecev po zadnji infuziji daratumumaba.
Darbepoetin alfa, the active substance in Aranesp, acts exactly like the natural erythropoietin made by the body to stimulate red blood cell production, but it is very slightly different in its structure.
Darbepoetin alfa, zdravilna učinkovina v zdravilu Aranesp, deluje povsem enako kot naravni eritropoetin, ki ga tvori telo za spodbujanje nastajanja rdečih krvničk, od njega se malce razlikuje le v zgradbi.
Darbepoetin alfa, the active substance in Nespo, acts exactly like the natural erythropoietin made by the body, but it is very slight different in its structure, and this means that darbepoetin alfa has a longer duration of action, and can be given less often than natural erythropoietin.
Darbepoetin alfa, zdravilna učinkovina zdravila Nespo, deluje natanko tako kot naravni eritropoetin, ki ga proizvaja telo,
Darifenacin AUC24 and Cmax from 30 mg once daily dosing in subjects who are extensive metabolisers were 95% and 128% higher when erythromycin (moderate CYP3A4 inhibitor) was co-administered with darifenacin than when darifenacin was taken alone.
AUC24 and Cmax darifenacina pri odmerku 30 mg enkrat dnevno pri osebah z obsežno presnovo sta bili za 95 % oziroma za 128 % večji, kadar so osebe dobivale sočasno z darifenacinom eritromicin (zmeren zaviralec CYP3A4), kot takrat, ko so dobivale samo darifenacin.
Darifenacin AUC24 and Cmax from 30 mg once-daily dosing in subjects who are extensive metabolisers were 95% and 128% higher when erythromycin (moderate CYP3A4 inhibitor) was co-administered with darifenacin than when darifenacin was taken alone.
AUC24 and Cmax darifenacina pri odmerku 30 mg enkrat dnevno pri osebah z obsežno presnovo sta bili za 95 % oziroma za 128 % večji, kadar so osebe dobivale sočasno z darifenacinom eritromicin (zmeren zaviralec CYP3A4), kot takrat, ko so dobivale samo darifenacin.
Darifenacin had no effect on male or female fertility in rats or any effect in the reproductive organs of either sex in rats and dogs (for details, see section 5.3).
Darifenacin ni vplival na plodnost samcev in samic pri podganah, prav tako ni vplival na spolne organe pri nobenem od obeh spolov pri podganah in psih (za podrobnosti glejte poglavje 5.3).
Darifenacin is a lipophilic base and is 98% bound to plasma proteins (primarily to alpha-1-acid- glycoprotein).
Darifenacin je lipofilna baza in se ga 98 % veže na plazemske beljakovine (predvsem na alfa-1-kisli- glikoprotein).
Darifenacin is extensively metabolised by the liver following oral administration.
Po peroralnem jemanju se darifenacin obsežno presnavlja v jetrih.
dark (tea-coloured) urine
temen urin (barve čaja)
Dark blue
temnomodra
Dark blue capsules, size 1, approximately 19 mm, imprinted “OPC 50” on the cap and “Bial” on the body.
Svetlomodre kapsule, velikost 1, približno 19 mm, z oznako »OPC 25« na pokrovčku in »Bial« na telesu.
Dark brownish red, oval, unscored film-coated tablets marked with ‘LCE 200’ on one side.
Temno rjavo-rdeče ovalne filmsko obložene tablete brez zareze z oznako »LCE 200« na eni strani.
Dark coloured urine
temno obarvan urin
dark or bloody stools, intense abdominal pain
črno ali krvavo blato, huda bolečina v trebuhu,
dark or bloody stools, intense abdominal pain,
črno ali krvavo blato, huda bolečina v trebuhu,
Dark peach opaque cap and dark peach opaque body, hard-shell
Zdravilo je na voljo v obliki trdih želatinastih kapsul in je sestavljeno iz neprozornega telesa in pokrovčka kapsule temno breskove barve.
dark urine
temen seč
dark urine
temen urin
dark urine confusion and/or disorientation.
temen seč, zmedenost in/ali dezorientacija.
Dark urine, blood in urine, difficulty urinating Dehydration
temen urin, kri v urinu, težave pri uriniranju; dehidracija;
Dark urine, urinary incontinence
temen urin, urinska inkontinenca
Dark yellow and white, printed with “3805”.
Temno rumene in bele barve, z napisom "3805".
Dark yellow to brownish orange oblong film-coated tablets with a score line on one side.
Temno rumena do rjavkastooranžna filmsko obložena tableta, okrogla in z zarezo na eni strani.
Dark yellow, capsule-shaped, debossed with “225” on one side.
Temno rumene barve, v obliki kapsule, z oznako " 225" na eni strani.
Dark yellow, convex, ovaloid tablet with a bevelled edge, with “T11” debossed on one side and “NVR” on the other.
Temno rumena konveksna ovalna tableta z zaobljenim robom, z oznako “T11” vtisnjeno na eni strani in oznako “NVR” na drugi.
Dark yellow, oval film-coated tablets debossed with ‘SP’ on one side and ‘100’ on the other side.
Temno rumene, ovalne filmsko obložene tablete z vtisnjeno oznako ‘SP’ na eni strani in oznako ‘100’ na drugi strani.
dark, cloudy or abnormally coloured urine,
temen, moten ali nenormalno obarvan seč,
dark, cloudy or abnormally coloured urine,
temen, moten ali nenormalno obarvan urin,
dark-coloured urine
temno obarvan seč
dark-coloured urine
temno obarvan urin
dark-coloured urine itching of your skin
temno obarvan urin, srbenje kože.
dark-coloured urine itching of your skin.
temno obarvan urin, srbenje kože.
dark/black blood in the stools
temno/črno krvjo v blatu
darkening of an area of skin (hyperpigmentation);
temneje obarvani predeli kože (hiperpigmentacija),
Darkening of the eyelashes, darkening of the iris colour, increased blinking, bleeding in the back of the eye (retinal bleeding), inflammation within the eye
temnenje trepalnic, temnenje irisa (šarenice), pogostejše mežikanje, krvavitev v ozadje očesa (krvavitev mrežnice), vnetje v očesu,
Darkening of your skin
potemnitev kože;
darkening skin colour
potemnitev kože
Darker eyelashes
temnejše trepalnice,
Darker eyelid colour
potemnitev vek,
Darker Iris colour
temnejša barva šarenice,
Darker skin colour around the eye
temnejša koža okrog očesa,
Daronrix is a vaccine that can only be used once a flu ‘pandemic’ has been officially declared by the World Health Organization (WHO) or European Union (EU).
Zdravilo Daronix je cepivo, ki se lahko uporablja šele potem, ko Svetovna zdravstvena organizacija (WHO) ali Evropska unija (EU) uradno razglasi pandemijo gripe.
Daronrix is a ‘mock-up’ vaccine.
Zdravilo Daronrix je »modelno« cepivo.
darunavir
(0,71-0,82)
Darunavir (300 mg once daily)/
darunavir (300 mg enkrat
Darunavir (600 mg twice daily)
darunavir (600 mg dvakrat dnevno)
darunavir 600 mg and ritonavir 100 mg twice daily
darunavir 600 mg in ritonavir 100 mg dvakrat na dan
Darunavir 600 mg twice daily with ritonavir 100 mg twice daily in antiretroviral treatment (ART) experienced patients.
Darunavir 600 mg dvakrat na dan z ritonavirjem 100 mg dvakrat na dan pri bolnikih, ki so bili predhodno zdravljeni z ART.
Darunavir 600 mg twice daily with ritonavir 100 mg twice daily in antiretroviral treatment. (ART) experienced patients.
Darunavir 600 mg dvakrat na dan z ritonavirjem 100 mg dvakrat na dan pri bolnikih, ki so bili predhodno zdravljeni z antiretrovirusno terapijo (ART).
Darunavir 800 mg once daily
darunavir 800 mg enkrat na dan
Darunavir 800 mg once daily with ritonavir 100 mg once daily may be used in some ART experienced patients.
Pri nekaterih bolnikih, ki so že bili zdravljeni z antiretrovirusno terapijo (ART), se lahko uporablja darunavir 800 mg enkrat na dan z ritonavirjem 100 mg enkrat na dan.
Darunavir 800 mg once daily with ritonavir 100 mg once daily may be used in some ART experienced patients.
Pri nekaterih bolnikih, ki so že bili zdravljeni z ART, se lahko uporablja darunavir 800 mg enkrat na dan z ritonavirjem 100 mg enkrat na dan.
Darunavir and Nevirapine Teva can be co-administered without dose adjustments.
Darunavir in zdravilo Nevirapin Teva se lahko uporablja sočasno brez prilagajanja odmerkov.
darunavir and ritonavir
darunavir in ritonavir
Darunavir and ritonavir are inhibitors of CYP3A, CYP2D6 and P-gp.
Darunavir in ritonavir sta zaviralca CYP3A, CYP26D in P-gp.
Darunavir and ritonavir are metabolised by CYP3A.
Darunavir in ritonavir se presnavljata z encimom CYP3A.
darunavir and ritonavir fosamprenavir and ritonavir
darunavirjem in ritonavirjem fosamprenavirjem in ritonavirjem
Darunavir and Viramune can be co- administered without dose adjustments.
Darunavir in Viramune lahko dajemo sočasno brez prilagajanja odmerkov.
Darunavir and Viramune can be co- administered without dose adjustments.
Darunavir in zdravilo Viramune lahko dajemo sočasno brez prilagajanja odmerkov.
Darunavir AUC ↑ 1.24 (0.97-1.57)
AUC darunavirja ↑ 1,24 (0,97-1,57)
darunavir AUC ↔
tenofovir AUC ↑ 22
Darunavir AUC  1.24 (0.97-1.57)
AUC darunavirja  1,24 (0,97-1,57)
Darunavir binds predominantly to 1-acid glycoprotein.
Darunavir se veže predvsem na plazemski alfa1- kisli glikoprotein.
Darunavir boosted with cobicistat is more sensitive for CYP3A induction than darunavir boosted with ritonavir.
Darunavir okrepljen s kobicistatom je bolj občutljiv za indukcijo s CYP3A kot darunavir okrepljen z ritonavirjem.
Darunavir boosted with cobicistat is more sensitive for CYP3A induction: concomitant use of darunavir/cobicistat and strong CYP3A inducers is therefore contraindicated (see section 4.3), and concomitant use with weak to moderate CYP3A inducers is not recommended (see section 4.5).
Darunavir, okrepljen s kobicistatom, je bolj občutljiv za indukcijo s CYP3A: sočasna uporaba učinkovin darunavir/kobicistat in močnih induktorjev CYP3A je kontraindicirana (glejte poglavje 4.3); sočasna uporaba s šibkimi ali zmernimi induktorji CYP3A ni priporočljiva (glejte poglavje 4.5).
Darunavir boosted with ritonavir (800 mg/ 100 mg once daily)/ ledipasvir (90 mg once daily)d
Z ritonavirjem okrepljeni darunavir (800 mg/ 100 mg enkrat na dan)/ ledipasvir (90 mg enkrat na dan)d
Darunavir boosted with ritonavirf (800/100 mg once daily)
Z ritonavirjem okrepljeni darunavirf (800/100 mg enkrat na dan)
Darunavir Cmax ↑ 1.40 (1.14-1.73)
Cmax darunavirja ↑ 1,40 (1,14-1,73)
darunavir Cmax ↓ 21%‡
uporaba okrepljenega zdravila
Darunavir Cmax  1.40 (1.14-1.73)
Cmax darunavirja  1,40 (1,14-1,73)
darunavir Cmin ↔
fumarat
Darunavir Cmin ↔ 1.02 (0.79-1.32)
Cmin darunavirja ↔ 1,02 (0,79-1,32)
Darunavir Cmin  1.02 (0.79-1.32)
Cmin darunavirja  1,02 (0,79-1,32)
Darunavir exhibits activity against laboratory strains and clinical isolates of HIV-1 and laboratory strains of HIV-2 in acutely infected T-cell lines, human peripheral blood mononuclear cells and human monocytes/macrophages with median EC50 values ranging from 1.2 to 8.5 nM (0.7 to ng/ml).
Darunavir je pokazal učinkovitost proti laboratorijskim sevom in kliničnim izolatom HIV-1 ter proti laboratorijskim sevom HIV-2 v akutno okuženih celičnih linijah T celic, človeških mononuklearnih celicah iz periferne krvi in človeških monocitih/makrofagih z medianimi vrednostmi EC50 v razponu od 1,2 do 8,5 nM (0,7 do 5,0 ng/ml).
Darunavir exposure (and also ritonavir exposure) may increase on stopping St John’s wort.
Po prekinitvi uporabe šentjanževke se lahko izpostavljenost darunavirju (in tudi ritonavirju) zveča.
Darunavir exposures in treatment-naïve adolescents 12 to 17 years weighing at least 40 kg receiving PREZISTA 800 mg once daily have been determined and were found to be within the therapeutic range as has been established in adults receiving PREZISTA 800 mg once daily.
Izpostavljenost darunavirju pri mladostnikih, ki še niso bili zdravljeni z ART, starih 12 do 17 let in s telesno maso najmanj 40 kg in so prejemali 800 mg zdravilaPREZISTA enkrat na dan, je bila ugotovljena in določena v enakem terapevtskem obsegu kot pri odraslih bolnikih, ki so prejemali prejemali 800 mg zdravilaPREZISTA enkrat na dan.
Darunavir FC was less than 10 for 90% of 3,309 clinical isolates resistant to amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir and/or tipranavir showing that viruses resistant to most PIs remain susceptible to darunavir.
FC darunavirja je manj kot 10za 90 % od 3.309 kliničnih izolatov, odpornih na amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir, sakvinavir in/ali tipranavir, kar pomeni, da virusi, odporni za večino zaviralcev proteaz, ostanejo občutljivi za darunavir.
Darunavir has different interaction profiles depending on whether the compound is boosted with ritonavir or cobicistat:
Darunavir ima različen profil medsebojnega delovanja z drugimi zdravili, ki je odvisen od tega ali je učinkovina okrepljena z ritonavirjem ali s kobicistatom:
darunavir is 800 mg once
darunavirja je
darunavir is 800 mg once
darunavirja je 800 mg
Darunavir is an inhibitor of the dimerisation and of the catalytic activity of the HIV-1 protease (KD of 4.5 x 10-12M).
Darunavir je zaviralec dimerizacije in katalitične aktivnosti proteaze HIV-1 (KD 4,5 x 10-12 M).
Darunavir may increase plasma concentrations of prednisone. (CYP3A inhibition)
Darunavir lahko zviša plazemske koncentracije prednizona. (zaviranje CYP3A)
Darunavir may therefore have different contraindications and recommendations for concomitant medications depending on whether the compound is boosted with ritonavir or cobicistat (see sections 4.3, 4.4 and 4.5).
Darunavir ima zato lahko različne kontraindikacije in priporočila za sočasno uporabo z drugimi zdravili, odvisno od tega ali je okrepljen z ritonavirjem ali s kobicistatom (glejte poglavja 4.3, 4.4 in 4.5).
darunavir or with
darunavirja ali pri odmerjanju
Darunavir pharmacokinetics parameters
Parametri farmakokinetike darunavirja
Darunavir, cobicistat and emtricitabine/tenofovir disoproxil fumarate (n = 50)
Darunavir, kobicistat in emtricitabin/ dizoproksiltenofovirat fumarat (n = 50)
Darunavir, dosed 800 mg once daily, if administered at the same time as ombitasvir/paritaprevir/ritonavir, can be used in the absence of extensive PI resistance (darunavir exposure lowered).
Darunavir v odmerku 800 mg enkrat na dan je mogoče uporabljati v kombinaciji z ombitasvirjem/paritaprevirjem/ritonavirjem, če se daje ob istem času in če ni obsežne odpornosti proti PI (zmanjšanje izpostavljenosti darunavirju).
darunavir, ritonavir concentrations were
koncentracije darunavirja in ritonavirja so
darunavir, the dose of Vitekta
darunavirjem mora biti odmerek
darunavir/
priporočljiv pri
Darunavir/ritonavir (600/100 mg twice daily or 800/100 mg once daily) in combination with a background regimen was evaluated in a clinical trial of 34 pregnant women (17 in each arm) during the second and third trimesters, and postpartum.
Darunavir/ritonavir (600/100 mg dvakrat na dan ali 800/100 mg enkrat na dan) v kombinaciji z osnovno shemo so ocenjevali v kliničnem preskušanju pri 34 nosečnicah (17 v vsaki skupini) med drugim in tretjim trimesečjem nosečnosti ter v obdobju po porodu.
darunavir/ritonavir 400/100 mg twice daily
1.000/400/100 mg dvakrat na dan
darunavir/ritonavir 400/100 mg twice daily
400/100 mg dvakrat na dan.
darunavir/ritonavir 400/100 mg twice daily
800/400/100 mg dvakrat na dan
darunavir/ritonavir 400/100 mg twice daily
darunavir/ritonavir 400/100 mg dvakrat na
darunavir/ritonavir 400/100 mg twice daily
enkrat na dan in darunavir/ritonavir
darunavir/ritonavir 600/100 mg
uporabiti režim odmerjanja
darunavir/ritonavir 600/100 mg twice daily regimen should be used.
Če se efavirenz uporablja v kombinaciji z darunavirjem/ritonavirjem, je treba uporabiti režim odmerjanja darunavir/ritonavir 600/100 mg dvakrat na dan.
darunavir/ritonavir 800/100 mg
darunavirjem/ritonavirjem
darunavir/ritonavir and telaprevir (see
telaprevirja ni priporočljiva (glejte
darunavir/ritonavir therapy.
izaviranja Pgp)
darunavir/ritonavir, the
darunavirjem/ritonavirjem, je treba
Darunavir/ritonavir/Efavirenz (300 mg b.i.d.*/100 mg b.i.d./600 mg q.d.)
darunavir/ritonavir/efavirenz (300 mg dvakrat dnevno*/100 mg dvakrat dnevno/600 mg dnevno)
Darunavir/ritonavir/efavirenz (300 mg twice daily*/100 mg twice daily/600 mg once daily)
(300 mg dvakrat na dan*/100 mg
Darunavir/Ritonavir/Emtricitabine
darunavir/ritonavir/emtricitabin
Darunavir:
darunavir
Darunavir:
darunavir/ritonavir/
Darunavir: AUC: ↓ 13%
(indukcija CYP3A4)
Darunavir: AUC: ↔
premljajočo sistemsko ali
Darunavir: comparison of
darunavir: primerjava jemanja učinkovin
Darunavir: comparison of
indinavir/darunavir/ritonavir
Darunavir: comparison of
ki zahtevajo farmakokinetično